Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tally Levy

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Acta Obstetricia Et Gynecologica Scandinavica|October 22, 2020
Age is an independent predictor of outcome in endometrial cancer patients: An Israeli Gynecology Oncology Group cohort studyNasreen Hag-Yahia, Ofer Gemer, Ram Eitan, et al.
American Journal of Clinical Oncology|March 4, 2015
Evaluation of Clinical and Pathologic Risk Factors May Reduce the Rate of Multimodality Treatment of Early Cervical CancerOfer Gemer, Ofer Lavie, Michael Gdalevich, et al.
American Journal of Obstetrics and Gynecology|May 25, 2018
Is there a survival advantage in diagnosing endometrial cancer in asymptomatic postmenopausal patients? An Israeli Gynecology Oncology Group studyOfer Gemer, Yakir Segev, Limor Helpman, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 5, 2014
Integration of PET/CT into the preoperative evaluation of patients with early cervical cancer does not decrease the proportion of patients with positive lymph nodes found after surgeryOfer Gemer, Ram Eitan, Michael Gdalevich, et al.
Gynecologic Oncology|May 30, 2018
Postoperative radiation rates in stage IIA1 cervical cancer: Is surgical treatment justified? An Israeli Gynecologic Oncology Group StudyYael Yagur, Omer Weitzner, Ofer Gemer, et al.
Gynecologic Oncology|June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trialGiorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2024
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapyChristof Vulsteke, Setsuko K Chambers, Maria Jesús Rubio Pérez, et al.
Gynecologic Oncology|May 13, 2022
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 studyRoisin E O'Cearbhaill, Jose-Alejandro Pérez-Fidalgo, Bradley J Monk, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2023
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial CancerIgnace Vergote, Jose Alejandro Pérez-Fidalgo, Erika Paige Hamilton, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Acta Obstetricia Et Gynecologica Scandinavica|October 22, 2020
Age is an independent predictor of outcome in endometrial cancer patients: An Israeli Gynecology Oncology Group cohort studyNasreen Hag-Yahia, Ofer Gemer, Ram Eitan, et al.
American Journal of Clinical Oncology|March 4, 2015
Evaluation of Clinical and Pathologic Risk Factors May Reduce the Rate of Multimodality Treatment of Early Cervical CancerOfer Gemer, Ofer Lavie, Michael Gdalevich, et al.
American Journal of Obstetrics and Gynecology|May 25, 2018
Is there a survival advantage in diagnosing endometrial cancer in asymptomatic postmenopausal patients? An Israeli Gynecology Oncology Group studyOfer Gemer, Yakir Segev, Limor Helpman, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 5, 2014
Integration of PET/CT into the preoperative evaluation of patients with early cervical cancer does not decrease the proportion of patients with positive lymph nodes found after surgeryOfer Gemer, Ram Eitan, Michael Gdalevich, et al.
Gynecologic Oncology|May 30, 2018
Postoperative radiation rates in stage IIA1 cervical cancer: Is surgical treatment justified? An Israeli Gynecologic Oncology Group StudyYael Yagur, Omer Weitzner, Ofer Gemer, et al.
Gynecologic Oncology|June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trialGiorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2024
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapyChristof Vulsteke, Setsuko K Chambers, Maria Jesús Rubio Pérez, et al.
Gynecologic Oncology|May 13, 2022
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 studyRoisin E O'Cearbhaill, Jose-Alejandro Pérez-Fidalgo, Bradley J Monk, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2023
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial CancerIgnace Vergote, Jose Alejandro Pérez-Fidalgo, Erika Paige Hamilton, et al.
Pageof 7